Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis

BACKGROUND. The randomized phase III RAINBOW trial established paclitaxel (pac) plus ramucirumab (ram) as a global standard for second‐line (2L) therapy in advanced gastric and gastroesophageal junction adenocarcinoma, together gastroesophageal adenocarcinoma (GEA). Patients (pts) receiving first‐li...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Klempner, Samuel J., Maron, Steven B., Chase, Leah, Lomnicki, Samantha, Wainberg, Zev A., Catenacci, Daniel V.T.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2018
Soggetti:
Gastrointestinal Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459251/
https://ncbi.nlm.nih.gov/pubmed/30470690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0602
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi